We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Aclaris Therapeutics, Inc.,today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering.